To the Editor.—
In the article on Fluosol-DA 20%,1 there is an error. A statement is made that the product is approved for marketing in Canada, Holland, and Italy. This is incorrect; Fluosol-DA 20% is not approved for marketing in Canada, although clinical studies are being performed there. In Holland, Fluosol-DA 20% is approved for "humanitarian use" in emergencies only, and in Italy, authorization to import Fluosol-DA 20% for the purpose of study under physician control was given.We regret any misunderstanding on this point and merely wish to set the record straight.
Carr M. Status of Fluosol-DA 20%. JAMA. 1984;251(22):2928. doi:10.1001/jama.1984.03340460018009